Business Context and Reporting Period
Immuron Limited, a foreign private issuer based in Australia, filed this Form 6-K on August 8, 2017. The filing serves to disclose two public announcements made to the Australian Securities Exchange (ASX) regarding corporate governance and clinical trial updates.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of specific events rather than a financial statement.
Material Changes and Events
- Director's Interest Notice: Director Mr. Peter Anastasiou purchased Immuron shares on-market.
- Clinical Data Presentation: The Company announced it will present data regarding C. difficile results at the 2017 ClostPath Conference in Michigan, USA.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future performance, or discussion of risks and contingencies. The document explicitly states it is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the specific volume and price of shares purchased by Director Peter Anastasiou in the attached Exhibit 99.1.
- Review the attached Exhibit 99.2 for the specific C. difficile data points to be presented at the ClostPath 2017 Conference.
- Confirm the date and location of the ClostPath Conference to assess the timeline for potential market impact.